Judith van Deutekom, PhD

Scientific co-founder and Advisor

Dr. van Deutekom is the scientific co-founder of VICO Therapeutics, and has an extensive track record in RNA modulating therapeutics. She has served as VP Drug Discovery at BioMarin Pharmaceutical Inc. and as Site Head of BioMarin Nederland from 2015-2019 and was CSO at Prosensa Therapeutics B.V. from 2007-2015.

She was one of the pioneers of the application of antisense oligonucleotides and the exon skipping technology for Duchenne Muscular Dystrophy (DMD) and has an extensive track record in the (pre)clinical development of antisense oligonucleotides for rare neuromuscular and neurodegenerative diseases since 1998.  She is (co)inventor on more than 15 patent families in that field.

Following her postdoctoral studies on gene therapy for DMD at University of Pittsburgh, she became a research staff member and assistant professor at the Department of Human Genetics of the Leiden University Medical Centre (LUMC), where she initiated the seminal work on exon skipping for DMD, which was later the foundation of Prosensa Therapeutics B.V.  She has been awarded for this research by the Princess Beatrix Muscle Foundation in 2001 and by the LUMC (C.J. Kok Award) in 2003. She is author on more than 80 publications in peer-reviewed scientific journals in the field of molecular biology and genetics, neuromuscular disorders and RNA therapeutics and holds a PhD degree on molecular genetics from Leiden University, The Netherlands.